Results for ipf translation from English to Estonian

time to first acute ipf exacerbation
aeg esimese akuutse ipf-i ägenemiseni

in ipf patients, lung function worsens over time.
idiopaatilise kopsufibroosiga patsientidel halveneb kopsufunktsioon aja jooksul.

the prognosis of ipf is poor and the survival rate is low.
ikf prognoos on halb ja elulemus madal.

nintedanib has been studied in clinical trials of 1,529 patients suffering from ipf.
nintedaniibi on kliinilistes uuringutes uuritud 1529 ipf-iga patsiendil.

treatment with ofev should be initiated by physicians experienced in the diagnosis and treatment of ipf.
ravi ofeviga tohib alustada idiopaatilise kopsufibroosi (ipf, idiopathic pulmonary fibrosis) diagnoosimise ja ravi kogemusega arst.

all adverse events of acute ipf exacerbation reported by the investigator were adjudicated by a blinded adjudication committee.
kõik uurija poolt teatatud akuutse ipf-i ägenemise kõrvaltoimed kontrolliti üle pimemenetletud kontrollikomitee poolt.

concomitant treatment of nintedanib with pirfenidone was investigated in a parallel group design study in japanese patients with ipf.
nintedaniibi kasutamist koos pirfenidooniga uuriti jaapanis ipf-iga patsientidel läbi viidud paralleelrühmadega uuringus.

esbriet is used to treat adults with mild to moderate idiopathic pulmonary fibrosis (ipf).
esbrieti kasutatakse kerge kuni mõõduka idiopaatilise kopsufibroosi raviks täiskasvanutel.

esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).
esbriet on näidustatud kerge kuni mõõduka idiopaatilise kopsufibroosi raviks täiskasvanutel.

by blocking these enzymes, nintedanib helps to reduce the formation of fibrous tissue in the lungs, thereby helping to prevent the symptoms of ipf from getting worse.
nende ensüümide blokeerimisega aitab nintedaniib vähendada fibroosse koe teket kopsus, takistades sellega idiopaatilise kopsufibroosi sümptomite süvenemist.

ambrisentan is therefore contraindicated for patients with ipf with or without secondary pulmonary hypertension (see section 4.3).
seetõttu on ambrisentaan vastunäidustatud patsientidele, kellel esineb idiopaatiline kopsufibroos koos sekundaarse pulmonaalhüpertensiooniga või ilma (vt lõik 4.3).

in its 1997 special session, the united nations general assembly has endorsed the proposals for action formulated in the framework of the intergovernmental panel on forests (ipf).
Üro peaassamblee kinnitas 1997. aasta eriistungjärgul oma tegevusettepanekud, mis esitati valitsustevahelisel metsanõupidamisel (ipf).